Biodrugs

Biodrugs英文簡(jiǎn)介

An essential resource for R&D professionals and clinicians with an interest in biologic therapies.

BioDrugs covers the development and therapeutic application of biotechnology-based pharmaceuticals and diagnostic products for the treatment of human disease.

BioDrugs offers a range of additional enhanced features designed to increase the visibility, readership and educational value of the journal’s content. Each article is accompanied by a Key Points summary, giving a time-efficient overview of the content to a wide readership. Articles may be accompanied by plain language summaries to assist patients, caregivers and others in understanding important medical advances. The journal also provides the option to include various other types of enhanced features including slide sets, videos and animations. All enhanced features are peer reviewed to the same high standard as the article itself. Peer review is conducted using Editorial Manager?, supported by a database of international experts. This database is shared with other Adis journals.

Biodrugs中文簡(jiǎn)介

《Biodrugs》是一本由ADIS INT LTD出版商出版的專業(yè)醫(yī)學(xué)期刊，該刊創(chuàng)刊于1994年，刊期Bimonthly，該刊已被國(guó)際權(quán)威數(shù)據(jù)庫(kù)SCIE收錄。在中科院最新升級(jí)版分區(qū)表中，該刊分區(qū)信息為大類學(xué)科：醫(yī)學(xué) 3區(qū)，小類學(xué)科：免疫學(xué) 3區(qū)；腫瘤學(xué) 3區(qū)；藥學(xué) 3區(qū)；在JCR（Journal Citation Reports）分區(qū)等級(jí)為Q1。該刊發(fā)文范圍涵蓋免疫學(xué)等領(lǐng)域，旨在及時(shí)、準(zhǔn)確、全面地報(bào)道國(guó)內(nèi)外免疫學(xué)工作者在該領(lǐng)域取得的最新研究成果、工作進(jìn)展及學(xué)術(shù)動(dòng)態(tài)、技術(shù)革新等，促進(jìn)學(xué)術(shù)交流，鼓勵(lì)學(xué)術(shù)創(chuàng)新。2021年影響因子為7.744，平均審稿速度>12周，或約稿。

中科院分區(qū)最新升級(jí)版（當(dāng)前數(shù)據(jù)版本：2021年12月最新升級(jí)版）

大類學(xué)科	分區(qū)	小類學(xué)科	分區(qū)	Top期刊	綜述期刊
醫(yī)學(xué)	3區(qū)	PHARMACOLOGY & PHARMACY 藥學(xué) IMMUNOLOGY 免疫學(xué) ONCOLOGY 腫瘤學(xué)	2區(qū) 3區(qū) 3區(qū)	否	否

JCR分區(qū)（當(dāng)前數(shù)據(jù)版本：2021-2022年最新版）

JCR分區(qū)等級(jí)	JCR所屬學(xué)科	分區(qū)	影響因子
Q1	ONCOLOGY	Q1	7.744
	PHARMACOLOGY & PHARMACY	Q1
	IMMUNOLOGY	Q1

期刊指數(shù)

影響因子	h-index	Gold OA文章占比	研究類文章占比	OA開(kāi)放訪問(wèn)	平均審稿速度
7.744	60	45.83%	61.70%	未開(kāi)放	>12周，或約稿

IF值(影響因子)趨勢(shì)圖